Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


One EU Pegfilgrastim Pulled As Another Launches

Executive Summary

As Stada and Gedeon Richter withdraw their applications for a pegfilgrastim biosimilar that the pair have been jointly developing, Mundipharma has pushed ahead with a European roll-out for its Pelmeg version starting in Germany, Ireland and the Netherlands.

You may also be interested in...

Mundipharma Gets Further CHMP Pegfilgrastim Nod

Mundipharma has received a positive opinion from the CHMP for its pegfilgrastim biosimilar. However, the firm would not be drawn on how this version fits into its strategy, given that it already markets its Pelmeg version that it obtained through its acquisition of Cinfa Biotech last year.

USV’s Juta Gets An EU Pegfilgrastim Nod

Juta Pharma has received a positive opinion from the European Medicines Agency’s CHMP recommending granting a pan-European marketing authorization for its biosimilar pegfilgrastim, Grasustek.

Napp Launches Mundipharma's Pelmeg In UK

Following launches of Mundipharma’s Pelmeg biosimilar pegfilgrastim in Germany, Ireland and the Netherlands, Napp is now rolling the product out in the UK.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts